First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors - Concepedia

Concepedia

Publication | Closed Access

First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors

86

Citations

27

References

2014

Year

Geoffrey I. Shapiro, Eunice L. Kwak, Bruce J. Dezube, Murray Yule, John Ayrton, John F. Lyons, Daruka Mahadevan

Clinical Cancer Research

Abstract

AT13387 administered once or twice weekly has an acceptable safety profile and demonstrated evidence of target engagement and preliminary antitumor activity.

References

	Year	Citations

Page 1